As Rod aptly put: Halo is not reinventing the wheel, just putting two approved drugs together. So far every trial is safe and effective. Building that database makes each successive trial easier and faster for each existing and new indication. Interesting that historical and other pre-clinical data was included in presentation.
This is the beauty of HALO as a biotech/pharma investment. We don't have to suffer the sturm und drang of sweating out FDA approval with each NDA. Safety and efficacy are largely in the bag here - and I'm talking about the whole pipeline! IMHO, its only a matter of jumping through the regulatory hoops to get to the goal line. Good luck! -Fritz
Market Data 
Markets 
AI
